It’s a groundbreaking moment for the UK’s nascent cannabis industry as Mamedica, the country’s up-and-coming medical cannabis clinic, collaborates with Cantourage UK to present its first-ever proprietary strains of cannabis. Already the top choice for patients seeking access, both present and future can now explore Mamedica’s exclusive branded cannabis flower.
- Mamedica partners with Cantourage to bring its first self-branded strains of THC-dominant Canadian cannabis to the UK.
- The partnership grants patients an avenue to high-quality, non-irradiated medical cannabis flowers grown meticulously by Miracle Valley, Cantourage’s premium cultivation partner.
- Mamedica data reveals an extraordinary 700% surge in patient numbers since 2023, underscoring public demand and awareness for medical cannabis.
- The tie-up signifies a vital enhancement for the UK cannabis industry, expanding the selection of top-tier international medical cannabis products to patients in need.
Cantourage UK has granted Mamedica access to Miracle Valley, a British Columbian-based licensed facility renowned for its craft-growing approach to producing prime medical cannabis under strictly regulated indoor conditions. This alliance provides patients suffering from a variety of health conditions with access to premium, THC-loaded, non-irradiated medical cannabis flowers.
Experiencing exponential growth since its 2022 inception, Mamedica has consistently furnished its patients with unmatched access to a broad array of standout cannabis-based prescription drugs encompassing flower, tinctures, vape cartridges, and capsules. Proof of its rapid success and the growing public awareness and demand for medical cannabis, Mamedica has reported a jaw-dropping 700 per cent increase in patient numbers since early 2023, with a forecast of further growth into next year.
Statements from Mamedica and Cantourage
Jon Robson, CEO, and Founder of Mamedica highlighted, “The partnership with Miracle Valley denotes a key milestone for Mamedica. It promotes our agenda to broaden our services and ensures patients have access to superior quality medical cannabis products.”
Simultaneously, Cantourage UK’s Co-Founder and COO, Niall Ivers, expressed pride in their partnership, lauding Mamedica’s commitment to patients and Cantourage UK’s capability to rally diverse stakeholders.
What BRITISH CANNABIS™ Has to Say
This historic stride in the UK cannabis industry indicates a promising future for patients who rely on effective, safe, and high-quality cannabis treatments. With an unwavering commitment to user safety and satisfaction, this partnership between Mamedica, Cantourage, and Miracle Valley sets a new benchmark in providing transformative cannabis-based solutions to patients across a spectrum of health conditions. The growth and efforts of these organizations reinforce the importance of reliable medical cannabis access in a market ready for expansion and innovation.